Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04740580 · ClinicalTrials.gov registry record · Early Phase 1
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
A Early Phase 1 study of Alzheimer Disease, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04740580: Recruiting Early Phase 1 study of Alzheimer Disease, sponsored by Baylor College of Medicine.
NCT04740580 is a Early Phase 1 study of Alzheimer Disease that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 52 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04740580, a Early Phase 1 study of Alzheimer Disease, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
Primary Outcome
Measured using ADAS-Cog testing
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Glycine
- DIETARY_SUPPLEMENT N-acetylcysteine
- DIETARY_SUPPLEMENT Alanine
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT04740580 shows while recruiting
NCT04740580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which Glycine is the first listed.
NCT04740580 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04740580 about?
NCT04740580 is a clinical study titled "Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease". Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcyst...
What is the current status of trial NCT04740580?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2022-02-15. Estimated completion is 2026-12-31.
What conditions does trial NCT04740580 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04740580?
The interventions under investigation include: Glycine (DIETARY_SUPPLEMENT), N-acetylcysteine (DIETARY_SUPPLEMENT), Alanine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04740580?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04740580 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04740580's enrollment target sits among peer trials
52 207th of 306 higher than 98 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Neuroinflammation Imaging in AD
RECRUITING · Early Phase 1
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
-
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI